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newborns with Down syndrome (DS) than in the population
of healthy children [1]. Mild isolated plasma thyrotropin
(TSH) elevation with normal thyroxine (T4) levels is the most
commonly seen pattern of thyroid dysfunction in these chil-
dren [2,3]. Other terminology used for this pattern of abnor-
mality includes isolated hyperthyrotropinemia, compensated
hypothyroidism, and subclinical hypothyroidism [4,5]. The
prevalence of mild TSH elevation (4–10 mIU/l) is estimated
at 80–90% in early infancy and 30–50% thereafter [3].
The cause of neonatal hypothyroidism in this particular
syndrome remains unclear; most patients have normal thyroid
scans excluding thyroid agenesis or ectopic thyroid tissue. The
absence of goiter suggests that it is not caused by dyshormono-
genesis [6,7]. Some authors suggested that it could be due to a
delay in the maturation of the hypothalamic-pituitary-thyroid
axis [8]. Others postulated that infants with transient TSH ele-
vation have a higher incidence of congenital malformations
than infants with permanent congenital hypothyroidism [9].
So, it may be hypothesized that newborns with congenital mal-
formations similar to DS suffer perinatal stress, which may
lead to TSH elevation [10].
Other possible explanations include an inappropriate
release of TSH related to a central disorder, the production
of a less active form of TSH, or some form of TSH insensitivity
in the thyroid gland [11].
The issue whether treatment of this mild form of subclinical
hypothyroidism is beneficial to children with DS is still contro-
versial especially that this particular type of thyroid dysfunc-
tion is self-limiting and high TSH tends to normalize
spontaneously in most of the DS patients [11]. Keeping in mind
that elevated TSH levels in early life cannot predict the develop-
ment of manifest thyroid disease later in childhood [12].
It is known that mild thyroid insufficiency may diminish tis-
sue sensitivity to growth hormone in normal children [13]. The
same occurs in children with DS. Sharav et al. reported that
growth in DS children with a TSH value >5.7 mIU/l was par-
ticularly retarded in comparison to the general population of
children [14].
On the other hand, Selikowitz annually assessed the health
condition of 101 children with DS. No significant differences ingrowth and development between those with subclinical hypo-
thyroidism and those with normal thyroid function were
revealed [15]. Also, Gruneiro de Papendieck et al. did not
notice a significant difference in height SDS between groups
of children with TSH levels below and above 5 mIU/l [16].
Later, a randomized double-blind 24-month trial compris-
ing 196 DS neonates with subclinical or overt hypothyroidism
was found to have a statistically significant difference in length
and weight gains between treated and placebo groups [17].
This was further supported by Kowalczyk et al. [18] work
which showed that early administration of L-thyroxin DS
children with subclinical or overt hypothyroidism results in a
significant improvement in the growth of these children [18].
Not only their physical growth but they also noticed a signif-
icant improvement in their psychomotor development [18].
Moreover, subclinical hypothyroidism may also signifi-
cantly increase hypotonia and anemia in these children [19].
Subclinical hypothyroidism has also been associated with
hypercholesterolemia atherosclerosis and eventually coronary
heart disease particularly in those with a TSH concentration of
10 mIU/L or greater [20,21]. Moreover, subclinical hypothy-
roidism increases arterial stiffness anddiastolic dysfunction [22].
It has long been known that DS patients have higher cho-
lesterol levels [23] and recently they were found to have a sig-
nificantly higher left ventricular diastolic dysfunction than that
observed in the controls [24]. So not giving L-thyroxin to sub-
clinical hypothyroidism in DS children would further increase
their cholesterol level, diastolic dysfunction and their risk of
coronary heart disease.
In conclusion, subclinical hypothyroidism is the most com-
mon thyroid dysfunction in DS. Although it is a self-limiting
condition, L-thyroxin administration will improve growth,
hypotonia and psychomotor functions. It may also decrease
the risk of hypercholesterolemia, hypertension and eventually
coronary heart disease in these children.
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